Jonathan Eckard has served as Tyme's Chief Scientific Affairs Officer since 2017 and assumed the role of Chief Business Officer in March 2019. Dr. Eckard has over 12 years of financial experience in equity research, bringing to us both important industry insights and comprehensive understanding of the healthcare equity capital markets. From 2016 to 2017, Dr. Eckard was Chief Business and Strategy Officer of SELLAS Life Science, a private oncology-focused biotechnology company. His previous finance roles include equity research analyst roles at Barclays Capital Markets, Citi Capital Markets, Leerink Swann, and HSBC Securities.

In this episode, we get a behind the scenes peek at:

- How the concept of SM-88 has evolved.

- What makes SM-88 different from other types of cancer therapies?

- Why SM-88 offers fewer side effects than common cancer therapies.

- How Tyme’s approach may be applicable to a variety of cancers.